ACUMEN PHARMACEUTICALS INC (ABOS)
Health Care · Alzheimer's disease / neurodegeneration therapeutics · NASDAQ
Clinical-stage biotech developing sabirnetug, a monoclonal antibody that targets amyloid-beta oligomers to modify disease progression in Alzheimer's patients, with Phase 2 results expected in late 2026.
What ACUMEN PHARMACEUTICALS INC does
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting amyloid-beta oligomers (AßOs), which are believed to be a primary driver of Alzheimer's disease pathology. The company's lead product candidate, sabirnetug (ACU193), is a humanized monoclonal antibody currently in Phase 2 clinical trials (ALTITUDE-AD) designed to selectively target and neutralize AßOs. Acumen is also developing an Enhanced Brain Delivery (EBD) technology platform in collaboration with JCR Pharmaceuticals to create blood-brain barrier-penetrating therapies for Alzheimer's disease and potentially other neurodegenerative conditions.
Themes: ["Alzheimer's disease / neurodegeneration","Amyloid-beta targeting","Monoclonal antibody therapeutics","Immunotherapy","CNS drug delivery"]
Fundamentals
- Price$2.70 as of 2026-07-09 close
- Market cap$195M as of 2026-07-10
- 1-year return+125.6% as of 2026-07-09 close
- Net margin-509.7% as of 2026-07-10
- ROE-123.1% as of 2026-07-10
- Debt / equity0.35 as of 2026-07-10
- Beta0.31 as of 2026-07-10
Key risks (from latest filing)
["Sabirnetug is still in Phase 2 development; ALTITUDE-AD top-line results are expected in late 2026, with substantial risk of failure to meet primary endpoints or demonstrate adequate safety/efficacy in a larger patient population","Dependence on third-party manufacturers and clinical trial vendors; inability to secure manufacturing capacity or contract research organization performance could delay development timelines","Significant cash burn and unprofitability (-509.72% net margin); reliance on future funding to advance sabirnetug and the EBD program, with substantial going-concern risk if funding cannot be secured"]
Competitors & peers
- Eli Lilly (LLY) — lecanemab and donanemab (anti-amyloid monoclonal antibodies)
- Biogen (BIIB) — aducanumab (anti-amyloid therapy)
- Roche / AC Immune — monoclonal antibodies against amyloid pathology
- Eisai (ESAI) — lecanemab co-developer
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.